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The authors for this paper wish to apologize for an error in ﬁgure 1 of their paper. The correct version appears below.
Figure 1. A: Design of ret/PTC1 small interfering RNAs (siRNAs). Location of ret/PTC1 sense sequence of siRNA nos. 1, 2, 3, 4 and 5 examined in
this study are shown under the junction sequence of ret/PTC1. The ret part of the oncogene is presented on the right part (g). B: The control
sequence is the sequence #5 with four mismatches. Mismatch site is shown in boxes. C: Structure of the shRNA1 and negative control shRNA.
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